MedTrace Logo

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-07-20

Study results available
· View outcomes & findings →

Summary

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

10mg

DRUG

Exenatide

Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)

DRUG

Placebo

Placebo for Dapagliflozin

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Eugenio Cersosimo, MD,PhD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2022-07-14
Completion
2023-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02981069 on ClinicalTrials.gov